Friday, December 10, 2021 8:42:53 AM
The problem with the appeal here is Cozen O'Connor. Sort of unbelievable that HCMC would consider keeping them. The loss below was caused by none other than Cozen O'Connor's stupidity in attaching evidence that, when credited, disproves HCMC's case.
That being said, HCMC now has to decide whether they want to revive a case accusing a product that is no longer sold in the United States of infringement of a United States Patent. Honestly, it makes no sense unless PM resumes sales.
The decision is not with prejudice. There has been no finding that the patent is not infringed. The case can be refiled. But why would HCMC do that when PM is not even selling the product here.
Now, HCMC has to potentially defend an IPR all for nothing. Now HCMC might take an appeal just to bring a case back against a product that is not even sold in the US and therefore creates very little in damages and recovery. Thanks Cozen O'Connor. Yes, HCMC, see what Cozen O'Connor advises. It has worked out so great thus far.
The most laughable part of Judge Batten's decision to dump the case is where he justifies his conclusion to dump the case based on the FDA documents with the following statement "the court cannot ignore what is in front of it", referring to Exhibit J. But nowhere does the court address the expert evidence of combustion. In other words, the court did exactly what the court said it could not do, i.e., "ignore what is in front of it." He ignored the expert evidence. So he can't "unsee" the FDA docs but he can totally ignore the expert evidence. It makes no sense. Batten elevated to primary significance a wholly conclusory statement in an FDA document while ingoring actual differential scanning calorimetry data provided by a PHD/Chemist that contradicted the conclusory statement that he cited as the basis for the dismissal. That created an issue of fact that should not be resolved on a Motion to Dismiss. Bottom line, Batten just cherry picked what he wanted to cherry pick and then decided based on that. That's your appeal. But does it matter? None of this matters at the moment. PM is not selling this product in the US. Very little damages at the moment. Very little can be recovered at the moment. That is the larger more strategic problem.
Recent HCMC News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/23/2024 09:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 02:06:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:54:19 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/03/2023 09:30:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2023 11:28:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2023 11:25:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2023 11:21:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/08/2023 08:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2023 08:00:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2023 09:11:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/21/2023 08:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2023 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2023 08:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 09:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/28/2023 08:25:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM